Videos and education on RUKOBIA (fostemsavir)

Access the resources below for additional details about RUKOBIA

Learn about the challenges faced by people living with MDR HIV-1.
Additional topics include:

Mechanism of action
BRIGHTE trial information
Dosing and drug interactions
Full Prescribing Information

BRIGHTE Educational Series

VO: RUKOBIA Educational Series

Visual: RUKOBIA EDUCATIONAL SERIES and logos appear on screen.

VO: Heavily treatment-experienced patients.

Visual: HEAVILY TREATMENT-EXPERIENCED PATIENTS appears on the screen and then fades out

VO: Indication. RUKOBIA, used with other HIV-1 medicines, is indicated for heavily treatment-experienced adults with multidrug-resistant HIV-1 who are failing their current ARV regimen. Important Safety Information. Contraindications. Do not use in patients with previous hypersensitivity to fostemsavir or any of the components of RUKOBIA. Do not use RUKOBIA in patients receiving strong cytochrome P450 (CYP)3A inducers, including those listed here. Please see additional Important Safety Information for RUKOBIA at the end of the video. Please click the link on this page to view the full Prescribing Information for RUKOBIA.

Visual: The RUKOBIA indication, contraindications, redirect to the additional Important Safety Information at the end of the video, and link to the full Prescribing Information. The length of time supers appear on screen aligns with VO narration.

VO: Treatment advances have largely trans-formed HIV-1

Visual: A light bulb, arrow, and TREATMENT ADVANCES are drawn.

VO: into a chronic, manageable condition, with life expectancies approaching that for people without HIV-1.

Visual: HIV-1 TODAY and the pill box icon are added. MANAGEABLE CONDITION FOR MANY PATIENTS is written at the end of the arrow.

VO: Yet, for the subpopulation of HIV-1 patients who are heavily treatment-experienced, or HTE, the outlook is often much different.

Visual: An icon of 3 people is drawn, and HEAVILY TREATMENT-EXPERIENCED is written.

VO: Some patients in this group are running out of treatment options due to

Visual: A down arrow and TREATMENT OP-TIONS are added to the frame.

VO: drug resistance, safety and tolerability issues, drug interactions, and comorbidities.

Visual: The factors that limit treatment options are added to the frame.

VO: As a result of their failing regimens, Visual: The FAILING REGIMENS icon is drawn.

VO: these patients may be struggling to maintain virologic suppression, are at increased risk of transmission, may become immunocompromised and at risk of opportunistic infections, and are at higher risk of HIV-1 disease progression and death.

Visual: The risks of failing regimens are added to the frame.

VO: How HIV-1 patients become HTE is varied and complex.

Visual: HOW PATIENTS BECOME HTE is written, and multiple intersecting arrows are drawn.

VO: The accumulation of resistance mutations may prevent the consideration of newer agents within a given therapeutic class.

Visual: RESISTANCE MUTATIONS is written, followed by a shield icon. An arrow pointing down is drawn, and MAY PREVENT USE OF is written at its end. NEWER AGENTS is written and crossed out.

VO: Some HTE patients have accumulated resistance mutations due to extensive exposure to early ARVs that are now known to be suboptimal.

Visual: EXTENSIVE SUBOPTIMAL ARV EXPOSURE is written, and a clipboard icon is drawn.

VO: Additionally, resistance may have developed in HTE patients who struggled with adherence due to interruptions in care.

Visual: A weekly pill box is drawn and crossed out.

VO: Whatever combination of factors has left them with limited ARV options, some HTE patients living with HIV-1

Visual: A down arrow is drawn, and LIMITED ARV OPTIONS is written next to it. The HTE icon and label are added to the frame.

VO: are in need of ARV classes

Visual: IN NEED OF is written, and an arrow is drawn pointing to the right.

VO: with novel mechanisms of action that have favorable resistance profiles.

Visual: A microscope icon is drawn, and ARV CLASSES WITH NOVEL MOAs is written.

VO: Important Safety Information, continued. Warnings and Precautions. Immune Reconstitution Syndrome and autoimmune disorders have been reported with the use of RUKOBIA. QTc prolongation has occurred with higher than recommended dosages of RUKOBIA. Use RUKOBIA with caution in patients with a history of QTc interval prolongation or cardiac disease, or who are taking drugs with a known risk of Torsade de Pointes. Elderly patients may be more susceptible. Monitoring of liver chemistries is recommended in patients with hepatitis B and/or C co-infection. Diligence should be applied when starting RUKOBIA in patients receiving hepatitis B therapy. Adverse reactions or loss of virologic response due to drug interactions may occur when using RUKOBIA with other drugs. Adverse Reactions. The most common adverse reaction reported with RUKOBIA was nausea.

Visual: Important Safety Information scrolls on screen.

VO: Drug interactions. See the full Prescribing Information for RUKOBIA for all significant drug interactions. Temsavir may increase plasma concentrations of grazoprevir and voxilaprevir. Use an alternative hepatitis C virus regimen, if possible. Use the lowest possible starting dose for statins with careful monitoring. Patients receiving RUKOBIA should not take estrogen-based therapies that contain more than 30 micrograms per day of ethinyl estradiol. Use RUKOBIA with caution in patients with additional risk factors for thromboembolic events. Use in Specific Populations. There are insufficient data on the use of RUKOBIA during pregnancy to assess drug-associated risks. Potential risks of breastfeeding include HIV 1 transmission, developing viral resistance in HIV-positive infants, and adverse reactions in the infant. Please click on the link on this page to view the full Prescribing Information for RUKOBIA.

Visual: Important Safety Information scrolls on screen.

REFERENCES:

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Updated December 18, 2019. Accessed May 7, 2020.
Thompson M, Lalezari JP, Kaplan R, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial. Antivir Ther.2017;22(3):215-223.
U.S. Department of Health and Human Services. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Updated November 21, 2019. Accessed May 9, 2020.
HIV Treatment and care. Centers for Disease Control and Prevention website. https://cdc.gov/hiv/clinicians/treatment/treatment-clinicians.html. Accessed May 9, 2020.
Data on file, ViiV Healthcare.

Introduction to people living with MDR HIV-1

Consider challenges faced by people living with MDR HIV-1 and limited antiretroviral (ARV) options

VO: RUKOBIA Educational Series

Visual: RUKOBIA EDUCATIONAL SERIES and logos appear on screen.

VO: Mechanism of action.

Visual: MECHANISM OF ACTION appears on the screen.

VO: Indication. RUKOBIA, used with other HIV-1 medicines, is indicated for heavily treatment-experienced adults with multidrug-resistant HIV-1 who are failing their current ARV regimen. Important Safety Information. Contraindications. Do not use in patients with previous hypersensitivity to fostemsavir or any of the components of RUKOBIA. Do not use RUKOBIA in patients receiving strong cytochrome P450 (CYP)3A inducers, including those listed here. Please see additional Important Safety Information for RUKOBIA at the end of the video. Please click the link on this page to view the full Prescribing Information for RUKOBIA.

Visual: The RUKOBIA indication, contraindications, redirect to the additional Important Safety Information at the end of the vid

VO: First-in-class RUKOBIA

Visual: FIRST-IN-CLASS RUKOBIA is written on screen.

VO: is the first FDA-approved HIV-1 attachment inhibitor.

Visual: FIRST FDA-APPROVED HIV-1 ATTACHMENT INHIBITOR is written.

VO: Unlike previously approved classes that act by blocking entry following attachment of the glycoprotein 120, or gp120, viral envelope protein,

Visual: ARV CLASSES THAT BLOCK ENTRY, HIV-1, and CD4+ T-CELL are drawn.

VO: RUKOBIA acts on the HIV-1 virion before attachment of gp120 to prevent the earliest stage of HIV-1 and CD4+ T-cell engagement.

Visual: RUKOBIA, HIV-1, and CD4+ T-CELL are added to complete the frame.

VO: Temsavir, the active moiety of RUKOBIA, attaches to gp120 on the surface of HIV-1 virions, near the CD4 attachment site.

Visual: HIV-1, GP120, and TEMSAVIR are drawn.

VO: The attachment of temsavir locks gp120 into a closed formation that prevents the initial interaction between the virus and host immune cells, leaving CD4+ T-cells untouched.

Visual: PREVENTS INITIAL INTERACTION arm and CD4+ T-CELL membrane are drawn on screen.

VO: With the HIV-1 virions unable to attach to CD4+ T-cells, they are a target for elimination by the body’s immune response.

Visual: The HIV-1 virions and CD4+ T-cell are drawn. The arrow and IMMUNE RESPONSE are added to the frame.

VO: Important Safety Information, continued. Warnings and Precautions. Immune Reconstitution Syndrome and autoimmune disorders have been reported with the use of RUKOBIA. QTc prolongation has occurred with higher than recommended dosages of RUKOBIA. Use RUKOBIA with caution in patients with a history of QTc interval prolongation or cardiac disease, or who are taking drugs with a known risk of Torsade de Pointes. Elderly patients may be more susceptible. Monitoring of liver chemistries is recommended in patients with hepatitis B and/or C co-infection. Diligence should be applied when starting RUKOBIA in patients receiving hepatitis B therapy. Adverse reactions or loss of virologic response due to drug interactions may occur when using RUKOBIA with other drugs. Adverse Reactions. The most common adverse reaction reported with RUKOBIA was nausea.

Visual: Important Safety Information scrolls on screen.

VO: Drug Interactions. See the full Prescribing Information for RUKOBIA for all significant drug interactions. Temsavir may increase plasma concentrations of grazoprevir and voxilaprevir. Use an alternative hepatitis C virus regimen, if possible. Use the lowest possible starting dose for statins with careful monitoring. Patients receiving RUKOBIA should not take estrogen-based therapies that contain more than 30 micrograms per day of ethinyl estradiol. Use RUKOBIA with caution in patients with additional risk factors for thromboembolic events. Use in Specific Populations. There are insufficient data on the use of RUKOBIA during pregnancy to assess drug-associated risks. Potential risks of breastfeeding include HIV 1 transmission, developing viral resistance in HIV-positive infants, and adverse reactions in the infant. Please click on the link on this page to view the full Prescribing Information for RUKOBIA.

Visual: Important Safety Information scrolls on screen.

REFERENCES:

Thompson M, Lalezari JP, Kaplan R, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial. Antivir Ther. 2017;22(3):215-223.
FDA Approval of HIV Medicines. AIDSinfo website. https://aidsinfo.nih.gov/understanding-hiv-aids/infographics/25/fda-approval-of-hiv-medicines. Updated April 30, 2019. Accessed May 9, 2020.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Updated December 18, 2019. Accessed May 7, 2020.
Cahn P, Fink V, Patterson P. Fostemsavir: a new CD4 attachment inhibitor. Curr Opin HIV AIDS. 2018;13(4):341-345.

Novel mechanism of action

Discover the first-in-class attachment inhibitor that prevents HIV-1 from interacting with host immune cells

VO: RUKOBIA Educational Series

Visual: RUKOBIA EDUCATIONAL SERIES and logos appear on screen.

VO: Dosing and drug interactions.

Visual: DOSING AND DRUG INTERACTIONS appears on the screen and then fades out.

VO: Indication. RUKOBIA, used with other HIV-1 medicines, is indicated for heavily treatment-experienced adults with multidrug-resistant HIV-1 who are failing their current ARV regimen. Important Safety Information. Contraindications. Do not use in patients with previous hypersensitivity to fostemsavir or any of the components of RUKOBIA. Do not use RUKOBIA in patients receiving strong cytochrome P450 (CYP)3A inducers, including those listed here. Please see additional Important Safety Information for RUKOBIA at the end of the video. Please click the link on this page to view the full Prescribing Information for RUKOBIA.

Visual: RUKOBIA indication, contraindications, redirect to the additional Important Safety Information at the end of the video, and link to the full Prescribing Information.

VO: The recommended dose of RUKOBIA is one 600-mg tablet, taken orally, twice daily. RUKOBIA can be taken with or without food.

Visual: RUKOBIA and its dosing information are written.

VO: Tablets should be taken whole

Visual: A tablet is drawn. WHOLE is written inside of it. (NOT ACTUAL SIZE) is added to the frame.

VO: and should not be chewed, crushed, or split.

Visual: NOT is written, followed by the actions that should not be taken with a RUKOBIA tablet.

VO: For patients with renal or hepatic impairment, no dose adjustments are required.

Visual: RENAL OR HEPATIC IMPAIRMENT is written, followed by an arrow pointing to NO DOSE ADJUSTMENTS REQUIRED.

VO: The primary metabolic pathway of RUKOBIA is

Visual: PRIMARY METABOLIC PATHWAY is written, followed by RUKOBIA.

VO: through esterase hydrolysis and secondarily by pathways dependent on cytochrome P450 3A4, or CYP3A4.

Visual: A molecular structure is drawn and ESTERASE HYDROLYSIS is written.

VO: RUKOBIA may be coadministered with

Visual: RUKOBIA MAY BE COADMINISTERED WITH is written on screen.

VO: other HIV-1 ARVs, as well as with strong inhibitors of cytochrome P450, family 3, subfamily A, or CYP3A; breast cancer resistance protein, or BCRP; and/or P-glycoprotein, or P-gp,

Visual: Bulleted copy is written.

VO: without dose adjustments.

Visual: An arrow pointing right is drawn and WITHOUT DOSE ADJUSTMENTS is written.

VO: Prescribers should be aware of the contraindications with RUKOBIA.

Visual: RUKOBIA CONTRAINDICATIONS is written.

VO: RUKOBIA is contraindicated in patients who are taking strong CYP3A4 inducers, including but not limited to enzalutamide, carbamazepine, phenytoin, rifampin, mitotane, and St. John’s wort. This is due to the potential for decreased temsavir plasma concentrations, which may result in loss of virologic response.

Visual: STRONG CYP3A4 INDUCERS is written, followed by the list of drugs. POTENTIAL LOSS OF VIROLOGIC RESPONSE is added on the right.

VO: Use an alternative HCV regimen, if possible, when coadministering RUKOBIA with grazoprevir or voxilaprevir due to the potential for increased exposures of grazoprevir or voxilaprevir. Increased exposures of grazoprevir may increase the risk of ALT elevations.

Visual: USE ALTERNATIVE HCV REGIMEN, IF POSSIBLE is written, followed by remaining copy on the left side of the screen. The vial icon is drawn, followed by MAY INCREASE RISK OF ELEVATED ALT.

VO: Dose adjustment is also required for coadministration with oral contraceptive ethinyl estradiol. The daily dose of ethinyl estradiol should not exceed 30 micrograms.

Visual: COADMINISTERING RUKOBIA WITH ETHINYL ESTRADIOL is written on screen, followed by DAILY DOSE OF ETHINYL ESTRADIOL ≤30 mcg.

VO: There are considerations for coadministering RUKOBIA with statins.

Visual: COADMINISTERING RUKOBIA WITH STATINS is written.

VO: Use the lowest possible starting dose of

Visual: LOWEST POSSIBLE STARTING DOSE OF: is written

VO: rosuvastatin, atorvastatin, fluvastatin, pitavastatin, and simvastatin.

Visual: ROSUVASTATIN, ATORVASTATIN, FLUVASTATIN, PITAVASTATIN, and SIMVASTATIN are written.

VO: Careful monitoring for statin-related events is recommended.

Visual: CAREFUL MONITORING RECOMMEND-ED and a magnifying glass icon are added to the frame.

VO: Important Safety Information, continued. Warnings and Precautions. Immune Reconstitution Syndrome and autoimmune disorders have been reported with the use

of RUKOBIA. QTc prolongation has occurred with higher than recommended dosages of RUKOBIA. Use RUKOBIA with caution in patients with a history of QTc interval prolongation or cardiac disease, or who are taking drugs with a known risk of Torsade de Pointes. Elderly patients may be more susceptible. Monitoring of liver chemistries is recommended in patients with hepatitis B and/or C co-infection. Diligence should be applied when starting RUKOBIA in patients receiving hepatitis B therapy. Adverse reactions or loss of virologic response due to drug interactions may occur when using RUKOBIA with other drugs. Adverse Reactions. The most common adverse reaction reported with RUKOBIA was nausea.

Visual: Important Safety Information scrolls on screen.

VO: Drug Interactions. See the full Prescribing Information for RUKOBIA for all significant drug interactions. Temsavir may increase plasma concentrations of grazoprevir and voxilaprevir. Use an alternative hepatitis C virus regimen, if possible. Use the lowest possible starting dose for statins with careful monitoring. Patients receiving RUKOBIA should not take estrogen-based therapies that contain more than 30 micrograms per day of ethinyl estradiol. Use RUKOBIA with caution in patients with additional risk factors for thromboembolic events. Use in Specific Populations. There are insufficient data on the use of RUKOBIA during pregnancy to assess drug-associated risks. Potential risks of breastfeeding include HIV 1 transmission, developing viral resistance in HIV-positive infants, and adverse reactions in the infant. Please click on the link on this page to view the full Prescribing Information for RUKOBIA.

Visual: Important Safety Information scrolls on screen.

Dosing and drug interactions

Review recommended dosing, considerations for coadministration, and contraindications with RUKOBIA

Downloadable Resources

Image of downloadable full Prescribing Information for RUKOBIA

See full Prescribing
Information for RUKOBIA

Download full PI

Image of downloadable patient brochure for RUKOBIA

Explore the opportunities to optimize
ARV regimens with RUKOBIA

Download patient brochure

Image of downloadable patient ID tool for RUKOBIA

Information about treatment
with RUKOBIA for your patients

Download patient ID tool

Sign up for future updates

Stay connected

HIV-1=human immunodeficiency virus type-1; MDR=multidrug-resistant.

Reference:

Aberg JA, Shepherd B, Wang M, et al. Week 240 efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1. Infect Dis Ther. 2023;12(9):2321-2335. doi:10.1007/s40121-023-00870-6

PMUS-FSTWCNT250013

You are now leaving this site

Videos and education on RUKOBIA (fostemsavir)

Access the resources below for additional details about RUKOBIA

Learn about the challenges faced by people living with MDR HIV-1.
Additional topics include:

BRIGHTE Educational Series

Introduction to people living with MDR HIV-1

Novel mechanism of action

Dosing and drug interactions

Downloadable Resources

Sign up for future updates

INDICATION

IMPORTANT SAFETY INFORMATION

Contraindications

INDICATION

IMPORTANT SAFETY INFORMATION

Contraindications

Warnings and precautions

Adverse reactions

Drug interactions

Use in specific populations

Videos and education on RUKOBIA (fostemsavir)

Access the resources below for additional details about RUKOBIA

Learn about the challenges faced by people living with MDR HIV-1. Additional topics include:

BRIGHTE Educational Series

Introduction to people living with MDR HIV-1

Novel mechanism of action

Dosing and drug interactions

Downloadable Resources

Sign up for future updates

INDICATION

IMPORTANT SAFETY INFORMATION

Contraindications

INDICATION

IMPORTANT SAFETY INFORMATION

Contraindications

Warnings and precautions

Adverse reactions

Drug interactions

Use in specific populations

Learn about the challenges faced by people living with MDR HIV-1.
Additional topics include: